公开(公告)号：US20240197658A1

公开(公告)日：2024-06-20

申请号：US18531132

申请日：2023-12-06

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hoon HUR ,  In-Hye Ham

IPC: A61K31/167 ,  A61P35/00

CPC classification number: A61K31/167 ,  A61P35/00 ,  A61K2300/00

Abstract: Provided is a composition for inhibiting anti-cancer drug resistance comprising a compound represented by Chemical Formula 1 below as an active ingredient:






(wherein,
R1 and R2 are each independently hydrogen, substitutable linear or branched C1-C12 alkyl, substitutable C3-C12 cycloalkyl, or substitutable C6-C18 aryl,
R3 is carboxyl, hydroxyl, or acetyl, and
the substitution is performed by oxygen, nitrogen, sulfur, linear or branched C1-C6 alkyl, C6-C20 aryl, halogen, or a combination thereof).

公开(公告)号：US20230137861A1

公开(公告)日：2023-05-04

申请号：US17907791

申请日：2021-02-24

Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Hoon HUR ,  In-hye HAM ,  Dagyeong LEE

IPC: C12Q1/6886 ,  G01N33/574

Abstract: The present invention relates to: a biomarker composition for diagnosing diffuse type gastric cancer, containing, as an active ingredient, a TINAGL1 protein or a gene encoding the protein; and a medical use thereof. More specifically, it is ascertained that: the secretion of TINAGL1 increases in cancer-associated fibroblasts separated from a diffuse type gastric cancer tissue; TINAGL1 improves metastasis and tumor formation of diffuse type gastric cancer by activating FAK signaling of cancer cells; the increase in TINAGL1 expression is related to the prognosis of a diffuse type gastric cancer patient. Therefore, TINAGL1 can be provided as a biomarker for the diagnosis and prognosis prediction of diffuse type gastric cancer, and a TINAGL1 expression or activity inhibitor can be provided as an effective agent for treating diffuse type gastric cancer.